Matthew F. Brown

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball et al. · Science · 2003 · 670 citations · Full text

Medicine, Immunology, Pharmacology +17

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

Maria Dêbiec‐Rychter, Herlinde Dumez, Ian Judson et al. · European Journal of Cancer · 2004 · 442 citations

Medicine, Molecular Medicine, Oncology +14

Delineating the role of cooperativity in the design of potent PROTACs for BTK

Adelajda Zorba, Chuong Nguyen, Yingrong Xu et al. · Proceedings of the National Academy of Sciences · 2018 · 423 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +15

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

Mark E. Flanagan, Todd A. Blumenkopf, William H. Brissette et al. · Journal of Medicinal Chemistry · 2010 · 335 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors

Mark E. Flanagan, J. A. Abramite, Dennis P. Anderson et al. · Journal of Medicinal Chemistry · 2014 · 324 citations

Pharmacy, Chemistry, Medicinal Chemistry +15